A study of human lung tumors indicates that lung cancer patients who lack a particular protein may do more poorly than those with normal levels of that same protein.

Are you a smoker or former smoker and worried that you might have lung cancer? Find out whether lung CT scan screening is effective.

Lightening up instead of lighting up is the best thing to do to fight lung cancer. New research shows that giving up smoking can reduce the risk of dying from the disease by up to 70 percent.

Researchers affiliated with the European Organisation for Research and Treatment of Cancer (EORTC)-Lung Cancer Group have reported that patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) who respond to chemotherapy have equivalent survivals following radiotherapy or surgery. The details of this study appeared in the March 21, 2007 issue of the Journal of the National Cancer Institute.

Former Hollywood Police Chief Richard Witt should be enjoying a semblance of vindication right now. He tried to clean up the PD during his tenure and was fired for his efforts. Now some of the officers he tried to expunge are part of a scandal involving an FBI mafia sting. His whistleblower’s lawsuit with the city, which by all rights he should win, is expected to go to trial in July. But Witt, who lives in north Florida, has been hit with some very bad news. He was diagnosed last week with a particulary virulent form of lung cancer.

Alfacell Corporation today announced that in vivo study results demonstrating the potential of ONCONASE (ranpirnase) for the treatment of non-small cell lung cancer (NSCLC) were recently published in Anticancer Research.

As the late L.A. writer Cathy Seipp was pressed to point out that “lung cancer, which kills more people annually (about 163,000) than the next four most common cancers (colon, breast, pancreatic and prostate) combined, is terribly underfunded compared to other diseases: $950 in research money per lung cancer death, compared to $8,800 for?breast cancer and $34,000 for AIDS.”

The two biggest biotech companies, Genentech and Amgen, released negative news that caused their shares to fall sharply. The drop was enough to put all of biotech lower on a day when the general market was positive.

Genentech, a Northern California biotech with manufacturing facilities in Oceanside, said yesterday that outside researchers halted a trial of its second-biggest cancer drug after some patients developed holes in their gastrointestinal tract and windpipe.One patient died, a Genentech spokeswoman said.

The trial, which was being conducted by researchers at the Sarah Cannon Cancer Center in Nashville, Tenn., tested the drug Avastin in combination with radiation and chemotherapy on 29 patients with small-cell lung cancer.